Elevated levels of IFN-γ may be an independent predictor of disease recurrence and may be used to identify a group of early-stage melanoma patients who are more likely to have recurrence of disease and who may benefit from adjuvant therapies, including immunotherapies [49]. The gene discussed is IFNG; the disease is melanoma.